Study of TC011 for large B-cell lymphoma that has not responded to treatment
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether the experimental drug TC011 can help adults with a type of B-cell lymphoma that has come back or stopped responding after at least two rounds of chemotherapy. The study checks for safety and whether the treatment can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19 years or older
- You must have large B-cell lymphoma that has returned or not improved after at least two previous treatments
- You must have at least one tumor that is 1.5 cm or larger on a scan
- Your heart must pump at least 40% of blood out each beat (measured by LVEF)
- You must be well enough to undergo a procedure called leukapheresis, where white blood cells are collected
- You cannot have had certain prior therapies like CAR T-cell therapy or a stem cell transplant from a donor
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests CRC01, a lab-made immune cell therapy, for adults whose lymphoma or B-cell leukemia has come back or did not respond to treatment. If you qualify, the study aims to see how safe CRC01 is and whether it can shrink tumors and improve outcomes.
This trial tests a new type of immune cell that targets two markers (CD19 and CD22) on lymphoma cells. It is for patients whose lymphoma has come back or not responded after at least two prior treatments.
This trial tests a new drug called TRS005 combined with standard chemotherapy (cyclophosphamide, doxorubicin, and prednisone) for people who haven't yet been treated for a type of lymphoma called CD20-positive DLBCL. The goal is to see if adding TRS005 helps more people get better.
This trial tests a new injection, MTM-H-001, in adults whose B-cell lymphoma has returned or not responded after at least two prior treatments. The goal is to see if it can help control the cancer.
This trial tests a new type of immune cell therapy (TC011) for people with follicular lymphoma that has come back or not responded to at least two prior treatments. The treatment uses your own immune cells, which are modified to fight the lymphoma.
This trial tests a new T-cell therapy (EB103) for people with B-cell non-Hodgkin's lymphoma that has come back or stopped responding to treatment. It aims to see if the therapy is safe and effective.
Hear when a new Relapsed Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.